CTOs on the Move

Crinetics

www.crinetics.com

 
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.crinetics.com
  • 10222 Barnes Canyon Road Building 2
    San Diego, CA USA 92121
  • Phone: 858.450.6464

Executives

Name Title Contact Details

Funding

Crinetics raised $40M on 11/02/2015

Similar Companies

Theranos

Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.

iBio

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio`s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It`s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.

Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

89bio

We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

NextImage Medical

NextImage Medical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.